Apr 16 |
VBI Vaccines FY Non-GAAP EPS of $3.96
|
Apr 16 |
VBI Vaccines Reports Full Year 2023 Financial Results
|
Apr 11 |
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Apr 9 |
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Apr 9 |
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
|
Apr 3 |
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
|
Apr 2 |
VBI Vaccines expands collaboration with Canadian government
|
Apr 2 |
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
|
Feb 14 |
Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
|
Feb 14 |
VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences
|